Role Of Economic Evaluation In Investment Analysis In Biotech Sector !

Hi everyone,

I am wondering about the effects that economic evaluation such as cost-effectiveness analysis has on medical devices or drugs sales and revenues and as a result on companies valuations ? It seems that many countries around the world are adopting these HTA bodies. Meanwhile there is growing interests in the US to follow the same path !

Economic Evaluation Impact on Patient Access to Medicines and Biotechnology Sector | Abuhadida, MD, MSc | Journal of Health Care Finance (healthfinancejournal.com)

Frontiers | Companies' Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study (frontiersin.org)

Comments (1)

2mo 
WSO Monkey Bot, what's your opinion? Comment below:

Excepturi ratione deleniti esse voluptatibus dolorum error neque. Et ut est voluptas nisi. Libero cum veritatis maiores itaque aut.

Accusamus molestiae culpa maxime est et. Quae odio deleniti dicta soluta rem ut quod. Ut alias qui soluta rerum atque porro eos. Enim sunt nisi quo fuga ipsa nostrum. Ut suscipit saepe quasi maxime ut. Voluptas quos adipisci sit eligendi corrupti.

Blanditiis quibusdam delectus voluptatem doloremque quia. Facere non facere neque aut quaerat ipsam corrupti. Voluptatem ea dolorum soluta quae itaque sapiente quam deleniti. Eos deleniti quia fugit magni nam voluptas. Corrupti aut molestiae et corrupti. Quasi aperiam blanditiis suscipit est.

Start Discussion

Career Advancement Opportunities

March 2023 Private Equity

  • The Riverside Company 99.5%
  • Warburg Pincus 98.9%
  • Blackstone Group 98.4%
  • KKR (Kohlberg Kravis Roberts) 97.9%
  • Bain Capital 97.4%

Overall Employee Satisfaction

March 2023 Private Equity

  • Ardian 99.5%
  • The Riverside Company 98.9%
  • Blackstone Group 98.4%
  • KKR (Kohlberg Kravis Roberts) 97.9%
  • Bain Capital 97.4%

Professional Growth Opportunities

March 2023 Private Equity

  • The Riverside Company 99.5%
  • Bain Capital 98.9%
  • Warburg Pincus 98.4%
  • Blackstone Group 97.9%
  • Ardian 97.4%

Total Avg Compensation

March 2023 Private Equity

  • Principal (8) $676
  • Director/MD (22) $599
  • Vice President (85) $362
  • 3rd+ Year Associate (86) $276
  • 2nd Year Associate (192) $264
  • 1st Year Associate (372) $228
  • 3rd+ Year Analyst (28) $157
  • 2nd Year Analyst (79) $133
  • 1st Year Analyst (227) $122
  • Intern/Summer Associate (30) $80
  • Intern/Summer Analyst (288) $58